Department of Protein Science, Amgen Inc, Seattle, Washington 98119, USA.
J Biol Chem. 2010 Jun 18;285(25):19637-46. doi: 10.1074/jbc.M110.117382. Epub 2010 Apr 16.
Naturally occurring IgG antibodies are bivalent and monospecific. Bispecific antibodies having binding specificities for two different antigens can be produced using recombinant technologies and are projected to have broad clinical applications. However, co-expression of multiple light and heavy chains often leads to contaminants and pose purification challenges. In this work, we have modified the CH3 domain interface of the antibody Fc region with selected mutations so that the engineered Fc proteins preferentially form heterodimers. These novel mutations create altered charge polarity across the Fc dimer interface such that coexpression of electrostatically matched Fc chains support favorable attractive interactions thereby promoting desired Fc heterodimer formation, whereas unfavorable repulsive charge interactions suppress unwanted Fc homodimer formation. This new Fc heterodimer format was used to produce bispecific single chain antibody fusions and monovalent IgGs with minimal homodimer contaminants. The strategy proposed here demonstrates the feasibility of robust production of novel Fc-based heterodimeric molecules and hence broadens the scope of bispecific molecules for therapeutic applications.
天然存在的 IgG 抗体是二价和单特异性的。具有针对两种不同抗原的结合特异性的双特异性抗体可以使用重组技术生产,并预计具有广泛的临床应用。然而,多个轻链和重链的共表达常常导致污染物并带来纯化挑战。在这项工作中,我们使用选定的突变修饰了抗体 Fc 区域的 CH3 结构域界面,使得工程化的 Fc 蛋白优先形成异二聚体。这些新的突变在 Fc 二聚体界面上产生了改变的电荷极性,使得静电匹配的 Fc 链的共表达支持有利的吸引相互作用,从而促进所需的 Fc 异二聚体形成,而不利的排斥电荷相互作用抑制不需要的 Fc 同二聚体形成。这种新的 Fc 异二聚体形式用于生产双特异性单链抗体融合物和单价 IgGs,同二聚体污染物最少。这里提出的策略证明了新型基于 Fc 的异二聚体分子的稳健生产的可行性,从而拓宽了双特异性分子在治疗应用中的范围。